Department of Immunology, University Hospital and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
HLA. 2019 Dec;94 Suppl 2:25-29. doi: 10.1111/tan.13761.
Although complex approaches in haematopoietic stem cell transplantation (aHSCT) improved substantially in the last decades, considerable proportion of patients still suffer from life-threatening complications including graft versus host disease (GvHD). Great effort has therefore been dedicated to identification of biomarkers of the aHSCT outcome. Recently, prognostic scores for the prediction of GvHD and non-relapse mortality based on circulating molecules, such as tumour necrosis factor receptor-1, IL-33receptor (ST2) and regenerating islet-derived 3-alpha were proposed and evaluated in multicentre studies. Furthermore, several biomarkers, for example, ST2, represent promising targets for therapeutic intervention in severe GvHD. These results bring us closer to the clinical strategies to effectively control complications following aHSCT, and therefore to the tailored stem cell therapy with higher benefits for the patients.
尽管造血干细胞移植（aHSCT）的复杂方法在过去几十年中得到了极大的改进，但仍有相当一部分患者患有危及生命的并发症，包括移植物抗宿主病（GvHD）。因此，人们致力于识别 aHSCT 结果的生物标志物。最近，基于循环分子（如肿瘤坏死因子受体-1、IL-33 受体（ST2）和再生胰岛衍生 3-α）提出并评估了用于预测 GvHD 和非复发死亡率的预后评分，这些预后评分是在多中心研究中提出并评估的。此外，一些生物标志物，例如 ST2，代表了严重 GvHD 治疗干预的有前途的靶点。这些结果使我们更接近控制 aHSCT 后并发症的临床策略，从而实现针对患者的个体化干细胞治疗，以获得更高的益处。
